Ausgabe 1/2018
Inhalt (12 Artikel)
Die deutsche S3-Leitlinie zum Nierenzellkarzinom
Arndt-Christian Müller, Birgitt van Oorschot, Oliver Micke, Matthias Guckenberger
Salvage radiotherapy for macroscopic local recurrences after radical prostatectomy
Alan Dal Pra, Cedric Panje, Thomas Zilli, Winfried Arnold, Kathrin Brouwer, Helena Garcia, Markus Glatzer, Silvia Gomez, Fernanda Herrera, Khanfir Kaouthar, Alexandros Papachristofilou, Gianfranco Pesce, Christiane Reuter, Hansjörg Vees, Daniel Rudolf Zwahlen, Daniel Engeler, Paul Martin Putora
Pre-radiotherapy PSA progression is a negative prognostic factor in prostate cancer patients using 5‑alpha-reductase inhibitors
Daniel Taussky, Julie Piotte, Kevin C. Zorn, Marc Zanaty, Vimal Krishnan, Carole Lambert, Jean-Paul Bahary, Marie-Claude Beauchemin, Maroie Barkati, Cynthia Ménard, Guila Delouya
Postoperative radiotherapy for prostate cancer
Cora Waldstein, Wolfgang Dörr, Richard Pötter, Joachim Widder, Gregor Goldner
Dynamics of rectal balloon implant shrinkage in prostate VMAT
Ben G. L. Vanneste, Y. van Wijk, L. C. Lutgens, E. J. Van Limbergen, E. N. van Lin, K. van de Beek, P. Lambin, A. L. Hoffmann
Intensified preoperative chemoradiation by adding oxaliplatin in locally advanced, primary operable (cT3NxM0) rectal cancer
P. Kogler, A. F. DeVries, W. Eisterer, J. Thaler, L. Sölkner, D. Öfner
Air–electron stream interactions during magnetic resonance IGRT
Jong Min Park, Kyung Hwan Shin, Jung-in Kim, So-Yeon Park, Seung Hyuck Jeon, Noorie Choi, Jin Ho Kim, Hong-Gyun Wu
Lethal outcome after pelvic salvage radiotherapy in a patient with prostate cancer due to increased radiosensitivity
Antje Fahrig, T. Koch, M. Lenhart, P. Rieckmann, R. Fietkau, Luitpold Distel, B. Schuster
Morbidität und Letalität durch Meningeome nach kranialer Strahlentherapie
Anca-Ligia Grosu, Jamina Tara Fennell
Postoperative Strahlentherapie beim Prostatakarzinom
Tobias Finazzi, Frank Zimmermann
Konventionelle oder akzeleriert-hyperfraktionierte simultane Radiochemotherapie beim kleinzelligen Lungenkarzinom im Stadium „limited disease“?
Susanne Frosch, Esther G. C. Troost
Thank you to all reviewers of Strahlentherapie und Onkologie 2017
Rainer Fietkau, Frederik Wenz